Works Cited

1. Hunt D, Kuck S, Truitt L. Methamphetamine Use: Lessons Learned. Cambridge, MA: ABT Associates Inc.; 2006.

2. Degenhardt L, Topp L. "Crystal meth" use among polydrug users in Sydney's dance party subculture: characteristics, use patterns and associated harms. Int J Drug Policy. 2003;14(1):17-24.

3. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci. 2003;15(3):317-325.

4. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry. 2005;13(3):141-154.

5. Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J Psychoactive Drugs. 2000;32(2):137-141.

6. United Nations Office on Drugs and Crime. Regional Trends: East and Southeast Asia: Summary, Emerging Trends and Concerns. Available at http://www.unodc.org/documents/southeastasiaandpacific//2012/12/ats-2012/section/2012_Regional_ATS_Report_SEA.pdf. Last accessed June 4, 2020.

7. Edström B. The forgotten success story: Japan and the methamphetamine problem. Japan Forum. 2015;27(4):519-543.

8. Reuter P, Caulkins JP. Does precursor regulation make a difference? Addiction. 2003;98(9):1177-1179.

9. Kongsakon R, Papadopoulos KI, Saguansiritham R. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. Int Clinl Psychopharmacol. 2005;20(5):253-256.

10. Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis. 2002;21(1):21-34.

11. National Institute on Drug Abuse. What is the Scope of Methamphetamine Abuse in the United States? Available at https:// www.drugabuse.gov/publications/research-reports/methamphetamine/what-scope-methamphetamine-misuse-in-united-states. Last accessed June 4, 2020.

12. U.S. Drug Enforcement Administration. 2019 National Drug Threat Assessment Summary. Available at https://www.dea.gov/sites/default/files/2020-01/2019-NDTA-final-01-14-2020_Low_Web-DIR-007-20_2019.pdf. Last accessed June 4, 2020.

13. Dombrowski K, Crawford D, Khan B, Tyler K. Current rural drug use in the U.S. Midwest. J Drug Abuse. 2016;2(3):pii-22.

14. Artigiani EEH, McCandlish D, Wish ED. Methamphetamine: A Regional Drug Crisis. College Park, MD: National Drug Early Warning System; 2018.

15. Substance Abuse and Mental Health Services Administration. 2018 National Survey of Drug Use and Health: Detailed Tables. Available at https://www.samhsa.gov/data/release/2018-national-survey-drug-use-and-health-nsduh-releases. Last accessed June 4, 2020.

16. The Regents of the University of Michigan. Monitoring the Future Survey: 2016 Data from In-School Surveys of 8th-, 10th-, and 12th-Grade Students. Available at http://www.monitoringthefuture.org/data/16data.html#2016data-drugs. Last accessed June 4, 2020.

17. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 2005-2015. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-91, HSS publication no. (SMA) 17-5037. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.

18. HIPRC808. Drug Facts: Methamphetamine. Available at http://www.hiprc808.org/meth. Last accessed June 4, 2020.

19. Freese TE, Obert J, Dickow A, Cohen J, Lord RH. Methamphetamine abuse: issues for special populations. J Psychoactive Drugs. 2000;32(2):177-182.

20. Hawai`i Free Press. News Release: 2011 Hawaii Meth Use and Attitudes Survey Shows Significant Shifts in Attitudes Among Teens and Young Adults. Available at http://www.hawaiifreepress.com/ArticlesMain/tabid/56/ID/4586/Hawaii-Meth-Survey-Shows-Significant-Shifts-in-Attitudes.aspx. Last accessed June 4, 2020.

21. Redfield RR, Schuchat A, Dauphin L, Cono J, Richards CL, Iademarco MF. Youth risk behavior surveillance—United States, 2017. MMWR. 2018;67(8):1-114.

22. Wu LT, Schlenger WE. Psychostimulant dependence in a community sample. Subst Use Misuse. 2003;38(2):221-248.

23. Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat. 2003;24(3):267-277.

24. von Mayrhauser C, Brecht ML, Anglin MD. Use ecology and drug use motivations of methamphetamine users admitted to substance abuse treatment facilities in Los Angeles: an emerging profile. J Addict Dis. 2002;21(1):45-60.

25. Boles SM, Miotto K. Substance abuse and violence: a review of the literature. Aggress Violent Behav. 2003;8(2):155-174.

26. Rawson R, Huber A, Brethen P, et al. Methamphetamine and cocaine users: differences in characteristics and treatment retention. J Psychoactive Drugs. 2000;32(2):233-238.

27. National Highway Traffic Safety Administration. Drugs and Human Performance Fact Sheets: Methamphetamine (and Amphetamine). Available at https://www.wsp.wa.gov/breathtest/docs/webdms/DRE_Forms/Publications/drug/Human_Performance_Drug_Fact_Sheets-NHTSA.pdf. Last accessed June 4, 2020.

28. National Institute on Drug Abuse. The Neurobiology of Drug Addiction. Available at https://www.drugabuse.gov/publications/teaching-addiction-science/neurobiology-drug-addiction. Last accessed June 4, 2020.

29. Cornish JW, O'Brien CP. Crack cocaine abuse: an epidemic with many public health consequences. Annu Rev Public Health. 1996;17:259-273.

30. Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 2005;7(4):E847-E851.

31. Barr AM, Panenka WJ, MacEwan GW, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006;31(5):301-313.

32. Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013;129(3):167-179.

33. Harvey JA. Cocaine effects on the developing brain: current status. Neurosci Biobehav Rev. 2004;27(8):751-764.

34. Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine addiction. CNS Drugs. 2005;19(1):13-25.

35. Cartier J, Farabee D, Prendergast ML. Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances. J Interpers Violence. 2006;21(4):435-445.

36. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001;36(1):1-22.

37. Brecht ML, O'Brien A, von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. Addict Behav. 2004;29(1):89-106.

38. Cadet JL, Krasnova IN. Chapter 5: molecular bases of methamphetamine-induced neurodegeneration. Int Rev Neurobiol. 2009;88:101-119.

39. Salo R, Nordahl TE, Galloway GP, Moore CD, Waters C, Leamon MH. Drug abstinence and cognitive control in methamphetamine-dependent individuals. J Subst Abuse Treat. 2009;37(3):292-297.

40. van Holst RJ, Schlit T. Drug-related decrease in neuropsychological functions of abstinent drug users. Curr Drug Abuse Rev. 2011;4(1):42-56.

41. Copeland AL, Sorensen JL. Differences between methamphetamine users and cocaine users in treatment. Drug Alcohol Depend. 2001;62(1):91-95.

42. National Institute on Drug Abuse. DrugFacts: What is Methamphetamine? Available at https://www.drugabuse.gov/publications/drugfacts/methamphetamine. Last accessed June 4, 2020.

43. Rawson RA, Huber A, Brethen P, et al. Status of methamphetamine users 2–5 years after outpatient treatment. J Addict Dis. 2002;21(1):107-119.

44. Curtis EK. Meth mouth: a review of methamphetamine abuse and its oral manifestations. Gen Dent. 2006;54(2):125-129.

45. National Institute on Drug Abuse. Methamphetamine: Overview. Available at https://www.drugabuse.gov/publications/research-reports/methamphetamine/overview. Last accessed June 4, 2020.

46. Shearer J, Sherman J, Wodak A, van Beek I. Substitution therapy for amphetamine users. Drug Alcohol Rev. 2002;21(2):179-185.

47. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, et al. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev. 2010;29(1):12-20.

48. American Dental Association. Meth Mouth: How Methamphetamine Use Affects Dental Health. Available at https://www.mouthhealthy.org/en/az-topics/m/meth-mouth. Last accessed June 4, 2020.

49. London ED, Berman SM, Voytek B, et al. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry. 2005;58(10):770-778.

50. Tobias MC, O'Neill J, Hudkins M, Bartzokis G, Dean AC, London ED. White-matter abnormalities in brain during early abstinence from methamphetamine abuse. Psychopharmacology (Berl). 2010;209(1):13-24.

51. Bae SC, Lyoo IK, Sung YH, et al. Increased white matter hyperintensities in male methamphetamine abusers. Drug Alcohol Depend. 2006;81(1):83-88.

52. Kalechstein AD, Newton TF, Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci. 2003;15(2):215-220.

53. London ED, Simon SL, Berman SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61(1):73-84.

54. Simon SL, Dacey J, Glynn S, Rawson R, Ling W. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat. 2004;27(1):59-66.

55. Chang L, Smith LM, LoPresti C, et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Res. 2004;132(2):95-106.

56. Salo R, Ursu S, Buonocore MH, Leamon MH, Carter C. Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: a functional magnetic resonance imaging study. Biol Psychiatry. 2009;65(8):706-709.

57. Woods SP, Rippeth JD, Conover E, et al. Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology. 2005;19(1):35-43.

58. Sekine Y, Ouchi Y, Takei N, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63(1):90-100.

59. Popova NK. From genes to aggressive behavior: the role of serotonergic system. Bioessays. 2006;28(5):495-503.

60. Badawy AA. Alcohol and violence and the possible role of serotonin. Crim Behav Ment Health. 2003;13(1):31-44.

61. Krakowski M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning. J Neuropsychiatry Clin Neurosci. 2003;15(3):294-305.

62. de Almeida RM, Ferrari PF, Parmigiani S, Miczek KA. Escalated aggressive behavior: dopamine, serotonin and GABA. Eur J Pharmacol. 2005;526(1-3):51-64.

63. Iudicello JE, Woods SP, Vigil O, et al. Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. J Clin Exp Neuropsychol. 2010;32(7):704-718.

64. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158(3):377-382.

65. Kitamura O, Takeichi T, Wang EL, Tokunaga I, Ishigami A, Kubo S. Microglial and astrocytic changes in the striatum of methamphetamine abusers. Leg Med (Tokyo). 2010;12(2):57-62.

66. Nordahl TE, Salo R, Natsuaki Y, et al. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry. 2005;62(4):444-452.

67. Salo R, Buonocore MH, Leamon M, et al. Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: a proton MRS study. Drug Alcohol Depend. 2011;113(2-3):133-138.

68. Wang GJ, Volkow ND, Chang L, et al. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry. 2004;161(2):242-248.

69. Smith L, Yonekura ML, Wallace T, Berman N, Kuo J, Berkowitz C. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr. 2003;24(1):17-23.

70. Colby JB, Smith L, O'Connor MJ, Bookheimer SY, Van Horn JD, Sowell ER. White matter microstructural alterations in children with prenatal methamphetamine/polydrug exposure. Psychiatry Res. 2012; 204(2-3):140-148.

71. Alicata D, Chang L, Cloak C, Abe K, Ernst T. Higher diffusion in striatum and lower fractional anisotropy in white matter of methamphetamine users. Psychiatry Res. 2009;174(1):1-8.

72. Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011;186(2-3):356-361.

73. Dyer KR, Cruickshank CC. Depression and other psychological health problems among methamphetamine dependent patients in treatment: implications for assessment and treatment outcomes. Aust Psychol. 2005;40(2):96-108.

74. Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181-190.

75. Semple SJ, Grant I, Patterson TL. Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users. Subst Use Misuse. 2005;40(12):1797-1810.

76. Akiyama K, Saito A, Shimoda K. Chronic methamphetamine psychosis after long-term abstinence in Japanese incarcerated patients. Am J Addict. 2011;20(3):240-249.

77. Chen CK, Lin SK, Sham PC, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003;33(8):1407-1414.

78. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196-204.

79. Hser YI, Evans E, Huang YC. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat. 2005;28(1):77-85.

80. McKetin R, Lubman DI, Najman JM, Dawe S, Butterworth P, Baker AL. Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study. Addiction. 2014;109(5):798-806.

81. Cohen JB, Dickow A, Horner K, et al. Abuse and violence history of men and women in treatment for methamphetamine dependence. Am J Addict. 2003;12(5):377-385.

82. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

83. Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011;37(2):131-136.

84. Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004;13(3):248-255.

85. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide (3rd Edition). Available at https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/evidence-based-approaches-to-drug-addiction-treatment/behavioral-3. Last accessed June 4, 2020.

86. Gould TJ. Addiction and cognition. Addict Sci Clin Pract. 2010;5(2):4-14.

87. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005;78(2):125-134.

88. Smout MF, Longo M, Harrison S, Minniti R, Wickes W, White JM. Psychosocial treatment for methamphetamine use disorders: a preliminary randomized controlled trial of cognitive behavior therapy and acceptance and commitment therapy. Subst Abuse. 2010;31(2):98-107.

89. Voccia FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry. 2009;22(3):263-268.

90. Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorder: an update. J Subst Abuse Treat. 2002;23(2): 145-150.

91. Rawson RA, Marinelli-Casey P, Anglin MD, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99(6):708-717.

92. Feeney GFX, Connor JP, Young R, Tucker J, McPherson A. Improvement in measures of psychological distress amongst amphetamine misusers treated with brief cognitive-behavioral therapy (CBT). Addict Behav. 2006;31(10):1833-1843.

93. Yen CF, Wu HY, Yen JY, Ko CH. Effects of brief cognitive-behavioral interventions on confidence to resist the urges to use heroin and methamphetamine in relapse-related situations. J Nerv Ment Dis. 2004;192(11):788-791.

94. Alammehrjerdi Z, Briggs NE, Biglarian A, Mokri A, Dolan K. A randomized controlled trial of brief cognitive behavioral therapy for regular methamphetamine use in methadone treatment. J Psychoactive Drugs. 2019;51(3):280-289.

95. Shoptaw S, Huber A, Peck J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85(1):12-18.

96. Roll JM, Huber A, Sodano R, Chudzynsky JE, Moynier E, Shoptaw S. A comparison of five reinforcement schedules for use in contingency management-based treatment of methamphetamine abuse. Psychol Rec. 2006;56(1):67-81.

97. Petry NM, Peirce JM, Stitzer ML, et al. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry. 2005;62(10):1148-1156.

98. Corsi KF, Shoptaw S, Alishahi M, Booth RE. Interventions to reduce drug use among methamphetamine users at risk for HIV. Curr HIV/AIDS Rep. 2019;16(1):29-36.

99. Gunter TD, Black DW, Zwick J, Arndt S. Drug and alcohol treatment services effective for methamphetamine abuse. Ann Clin Psychiatry. 2004;16(4):195-200.

100. Kamp F, Proebstl L, Hager L, et al. Effectiveness of methamphetamine abuse treatment: predictors of treatment completion and comparison of two residential treatment programs. Drug Alcohol Depend. 2019;201:8-15.

101. Brecht ML, Anglin MD, Dylan M. Coerced treatment for methamphetamine abuse: differential patient characteristics and outcomes. Am J Drug Alcohol Abuse. 2005;31(2):337-356.

102. Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care. 2011;38(1):41-58, v-vi.

103. Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020;34(4):337-365.

104. Rose ME, Grant JE. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry. 2008;20(3):145-155.

105. Zorick T, Sugar CA, Hellemann G, Shoptaw S, London ED. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug Alcohol Depend. 2011;118(2-3):500-503.

106. Piasecki MP, Steinagel GM, Thienhaus OJ, Kohlenberg BS. An exploratory study: the use of paroxetine for methamphetamine craving. J Psychoactive Drugs. 2002;34(3):301-304.

107. Newton TF, Roache JD, De La Garza R 2nd, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006;31(7):1537-1544.

108. Pérez-Mañá C, Castells X, Torrens M, Capellà D, Farre M. Efficacy of psychostimulants drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev. 2013;9:CD009695.

109. Laqueille X, Dervaux A, El Omari F, Kanit M, Baylé FJ. Methylphenidate effective in treating amphetamine abusers with no other psychiatric disorder. Eur Psychiatry. 2005;20(5-6):456-457.

110. Galloway GP, Buscemi R, Coyle JR, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011;89(2):276-282.

111. Longo M, Wickes W, Smout M, Harrison S, Cahill S, White JM. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010;105(1):146-154.

112. De La Garza R 2nd, Zorick T, London ED, Newton TF. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend. 2010;106(2-3):173-180.

113. Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009;104(2):224-233.

114. Heinzerling KG, Swanson AN, Kim S, et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010;109(1-3):20-29.

115. McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat. 2008;35(3):334-342.

116. Heinzerling KG, Shoptaw S, Peck JA, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85(3):177-184.

117. Urschel HC 3rd, Hanselka LL, Baron M. A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. J Psychopharmacol. 2011;25(2):254-262.

118. Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55(5):122-125.

119. Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D. Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis. 1994;13(4):201-216.

120. Wachtel SR, Ortengren A, de Wit H. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend. 2002;68(1):23-33.

121. Johnson BA, Ait-Daoud N, Elkashef AM, et al.; Methamphetamine Study Group. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol. 2008;11(1):1-14.

122. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165(11):1442-1448.

123. Anggadiredja K, Sakimura K, Hiranita T, Yamamoto T. Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res. 2004;1021(2):272-276.

124. Lam L, Anand S, Li X, Tse ML, Zhao JX, Chan EW. Efficacy and safety of naltrexone for amfetamine and methamphetamine use disorder: a systematic review of randomized controlled trials. Clin Toxicol (Phila). 2019;57(4):25-233.

125. Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North Am. 2010;33(2):339-355.

126. International AIDS Society USA. Methamphetamine Use in Urban Gay and Bisexual Populations. Available at https://www.iasusa.org/wp-content/uploads/2006/06/14-2-84.pdf. Last accessed June 4, 2020.

127. Shoptaw S. Methamphetamine use in urban gay and bisexual populations. Top HIV Med. 2006;14(2):84-87.

128. Mausbach BT, Semple SJ, Strathdee SA, Patterson TL. Predictors of safer sex intentions and protected sex among heterosexual hiv-negative methamphetamine users: an expanded model of the theory of planned behavior. AIDS Care. 2009;21(1):17-24.

129. Peck JA, Shoptaw S, Rotheram-Fuller E, Reback CJ, Bierman B. HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. J Addict Dis. 2005;24(3):115-132.

130. Shoptaw S, Klausner JD, Reback CJ, et al. A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence. BMC Public Health. 2006;6:214.

131. Farabee D, Prendergast M, Cartier J. Methamphetamine use and HIV risk among substance-abusing offenders in California. J Psychoactive Drugs. 2002;34(3):295-300.

132. Parsons JT, Kowalczyk WJ, Botsko M, Tomassilli J, Golub SA. Aggregate versus day level association between methamphetamine use and HIV medication non-adherence among gay and bisexual men. AIDS Behav. 2013;17(4):1478-1487.

133. Moore DJ, Blackstone K, Woods SP, et al. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012;24(12):1504-1513.

134. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003;188(12):1820-1826.

135. Cherner M, Letendre S, Heaton RK, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005;64(8):1343-1347.

136. Kraman P. Trends Alert: Drug Abuse in America—Rural Meth. Lexington, KY: The Council of State Governments; 2004.

137. Clark JJ, Leukefeld C, Godlaski T. Case management and behavioral contracting components of rural substance abuse treatment. J Subst Abuse Treat. 1999;17(4):293-304.

138. Zorick T, Nestor L, Miotto K, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010;105(10):1809-1818.

139. MacDonald K, Wilson MP, Minassian A, et al. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients. Gen Hosp Psychiatry. 2010;32(4):443-445.

140. Petit JR. Management of the acutely violent patient. Psychiatr Clin North Am. 2005;28(3):701-711.

141. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010;32(3):403-425.

142. Humphreys K, Wing S, McCarty D, et al. Self-help organizations for alcohol and drug problems: toward evidence-based practice and policy. J Subst Abuse Treat. 2004;26(3):151-158.

143. Kadden RM, Litt MD. The role of self-efficacy in the treatment of substance use disorders. Addict Behav. 2011;36(12):1120-1126.

144. Kelly JF, Urbanoski KA, Hoeppner BB, Slaymaker V. Facilitating comprehensive assessment of 12-step experiences: a multidimensional measure of mutual-help activity. Alcohol Treat Q. 2011;29(3):181-203.

145. Lyons T, Chandra G, Goldstein J. Stimulant use and HIV risk behavior: the influence of peer support group participation. AIDS Educ Prev. 2006;18(5):461-473.

146. Paulus MP, Tapert SF, Schuckit MA. Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. Arch Gen Psychiatry. 2005;62(7):761-768.

147. Yen CF, Chang YP. Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents. Psychiatry Clin Neurosci. 2005;59(1):77-82.

148. Tuliao AP, Liwag ME. Predictors of relapse in Filipino male methamphetamine users: a mixed methods approach. J Ethn Subst Abuse. 2011;10(2):162-179.

149. Maglione M, Chao B, Anglin MD. Correlates of outpatient drug treatment drop-out among methamphetamine users. J Psychoactive Drugs. 2000;32(2):221-228.

Evidence-Based Practice Recommendations Citations

1. Management of Substance Use Disorders Work Group. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Washington, DC: Department of Veterans Affairs, Department of Defense; 2015. Available at https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf. Last accessed June 15, 2020.

2. Marcell AV, Male Training Center for Family Planning and Reproductive Health. Preventive Male Sexual and Reproductive Health Care: Recommendations for Clinical Practice. Philadelphia, PA: Male Training Center for Family Planning and Reproductive Health; 2014. Available at https://www.fpntc.org/sites/default/files/resources/mtc_male_prevrhc_2014.pdf. Last accessed June 15, 2020.


Copyright © 2020 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.